Denali offers more clues on clinical hold, turning over FDA worries on preclinical tox for Alzheimer's drug

Denali hit a major speed bump last month with the FDA hitting the pause button on its lead Alzheimer’s drug. Now, the biotech has offered …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

De­nali of­fers more clues on clin­i­cal hold, turn­ing over FDA wor­ries on pre­clin­i­cal tox for Alzheimer's drug